000			02002 a2200589 4500
005			20250517062910.0
264		0	_c20160819
008			201608s 0 0 eng d
022			_a1471-2407
024	7		_a10.1186/s12885-015-1900-y _2doi
040			_aNLM _beng _cNLM
100	1		_aZhu, Yan
245	0	0	_aDual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. _h[electronic resource]
260			_bBMC cancer _cNov 2015
300			_a894 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aCell Cycle _xdrug effects
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aDisease Models, Animal
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aG1 Phase Cell Cycle Checkpoints _xdrug effects
650	0	4	_aHumans
650	0	4	_aImidazoles _xpharmacology
650	0	4	_aMice
650	0	4	_aPhosphoinositide-3 Kinase Inhibitors
650	0	4	_aQuinolines _xpharmacology
650	0	4	_aReceptor, ErbB-2 _xmetabolism
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aStomach Neoplasms _xdrug therapy
650	0	4	_aTOR Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aTrastuzumab _xpharmacology
650	0	4	_aTumor Burden _xdrug effects
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aTian, Tiantian
700	1		_aZou, Jianling
700	1		_aWang, Qiwei
700	1		_aLi, Zhongwu
700	1		_aLi, Yanyan
700	1		_aLiu, Xijuan
700	1		_aDong, Bin
700	1		_aLi, Na
700	1		_aGao, Jing
700	1		_aShen, Lin
773	0		_tBMC cancer _gvol. 15 _gp. 894
856	4	0	_uhttps://doi.org/10.1186/s12885-015-1900-y _zAvailable from publisher's website
999			_c25441409 _d25441409